Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: AWeSoMe study group real-life observational experience

Acta Diabetologica
Z LandauMariana Rachmiel

Abstract

Frequent glucose testing is required for optimal management of type 1 diabetes (T1D). Limited data are available regarding real-world experience of the novel technology for monitoring by continuous interstitial fluid glucose (IFG), using flash glucose-sensing technology (FSL-CGM). We aimed to assess the effect of FSL-CGM in a real-life clinical setting on glycemic control parameters, compliance, and adverse events among pediatric and young adult T1D patients. This observational multi-center study assessed FSL-CGM use (6-12 months) in T1D patients (mean ± SD age 13.4 ± 4.9 years) who purchased the device out-of-pocket. Outcome measures included HbA1c, mean IFG levels, CGM metrics [time in hypoglycemia (< 54 mg/dL; < 3 mmol/L), in target range (70-180 mg/dL; 3.9-10 mmol/L), and in hyperglycemia > 240 mg/dL; > 13.3 mmol/L)], frequency of self-monitoring of blood glucose, acute complications, skin reactions, and reasons for initiation/discontinuation. Among patients with regular use of the FSL-CGM (n = 59), mean HbA1c decreased from 8.86 ± 0.23 to 8.05 ± 0.2% (73.3-64.5 mmol/mol) in 3 months (p = 0.0001) and plateaued thereafter. A clinically significant reduction in HbA1c (defined as a decrease of ≥ 0.5%) was associated with short...Continue Reading

Associated Clinical Trials

References

Sep 10, 2008·The New England Journal of Medicine·William V TamborlaneDongyuan Xing
Jul 1, 2010·The New England Journal of Medicine·Richard M BergenstalUNKNOWN STAR 3 Study Group
Feb 8, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·J HermanidesJ H DeVries
May 31, 2014·Journal of Diabetes Science and Technology·Kimberly EnglertUNKNOWN Diabetes Research in Children (DirecNet) Study Group
Jul 12, 2014·Diabetes Care·Jenise C WongUNKNOWN T1D Exchange Clinic Network
Aug 4, 2015·Diabetes Technology & Therapeutics·Ram WeissJohn J Shin
Nov 3, 2016·Journal of Diabetes Science and Technology·Maya Ish-ShalomOfri Mosenzon
Jul 29, 2016·Journal of Diabetes Science and Technology·Anna R DoverFraser W Gibb
Jan 20, 2017·Diabetic Medicine : a Journal of the British Diabetic Association·J A McKnight, F W Gibb
Feb 1, 2017·Archives of Disease in Childhood·Julie EdgeNicola Trevelyan
Apr 13, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Thomas HaakGerry Rayman
Apr 14, 2017·Lancet·Jan BolinderRaimund Weitgasser
Dec 14, 2017·Diabetes Technology & Therapeutics·Agnieszka SzadkowskaWojciech Młynarski
Jan 18, 2018·The Journal of Clinical Endocrinology and Metabolism·Sara CharleerUNKNOWN RESCUE Trial Investigators

❮ Previous
Next ❯

Citations

Jul 25, 2019·Diabetes Technology & Therapeutics·Stefan PleusGuido Freckmann
Aug 28, 2019·Journal of Diabetes Science and Technology·Nurul A Mohd AsaraniBenjamin J Wheeler
Nov 2, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Mark EvansAlexander Seibold
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Mar 25, 2020·Clinical Medicine Insights. Endocrinology and Diabetes·Ayman A Al HayekMohamed A Al Dawish
May 9, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ayman A Al Hayek, Mohamed A Al Dawish
Dec 11, 2020·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.